Completed PHASE1/PHASE2 INTERVENTIONAL 2-arm NCT01004120

Efficacy of a Prebiotic Galactooligosaccharide to Reduce Metabolic Syndrome Risk Factors in Overweight Adults

Double-blind, Placebo Controlled, Randomised, Cross-over Study to Determine the Effect of a Prebiotic Galactooligosaccharide on Microbiota and Metabolic Syndrome Risk Factors in Overweight Adults

Sponsor: Clasado

Conditions Metabolic Syndrome X

Interventions Bimuno Maltodextrin

Updated 5 times since 2017 Last updated: Mar 24, 2016 Started: Oct 31, 2009 Primary completion: Dec 31, 2011 Completion: Dec 31, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01004120, this PHASE1/PHASE2 trial focuses on Metabolic Syndrome X and remains completed. Sponsored by Clasado, it has been updated 5 times since 2009, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1_PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1_PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1_PHASE2

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Clasado
University of Reading

Data source: Clasado

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Reading, United Kingdom